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Abstract: The search for high relaxivities and increased specificity continues to be central to the
development of paramagnetic contrast agents for magnetic resonance imaging (MRI). Ferritin, due to
its unique surface properties, architecture, and biocompatibility, has emerged as a natural nanocage
that can potentially help to reach both these goals. This review aims to highlight recent advances in
the use of ferritin as a nanoplatform for the delivery of metal-based MRI contrast agents (containing
Gd3+, Mn2+, or Fe2O3) alone or in combination with active molecules used for therapeutic purposes.
The collected results unequivocally show that the use of ferritin for contrast agent delivery leads to
more accurate imaging of cancer cells and a significantly improved targeted therapy.
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1. Introduction
Specific delivery by naturally occurring macromolecules has been explored for a long time to
improve the diagnostic potential of magnetic resonance imaging (MRI) contrast agents (CAs). The MRI
signal is dependent on the longitudinal (T1) and transverse (T2) proton relaxation times of water
and, therefore, the image contrast arises mainly from differences in the T1 and T2 of tissue water
protons as a consequence of the water interaction with biological macromolecules and membranes.
In both clinical and experimental settings, the endogenous contrast can be altered by the use of CAs
that decrease the T1 and T2 of water protons in the tissues where they distribute [1–3], with the T1
and T2 values having opposite effects on the T1- and T2-weighted images. A T1 decrease causes a
signal intensity (SI) increase (positive contrast), whereas a T2 decrease causes an SI decrease (negative
contrast). The interaction of CAs with macromolecules (i.e., proteins) has the double advantage of
increasing both the targeted delivery and the contrast efficiency that is related to the tumbling rate
reduction. As CAs are intravenously administered, the first protein considered was serum albumin [4].
Binding with serum albumin modulates CA extravasation, thus allowing dynamic contrast enhanced
(DCE) protocols devoted to the detection of parameters related to vascular permeability and blood
flow to occur [5]. Lipoproteins have also been proposed in many preclinical studies for the delivery
of lipophilic CAs with the aim of targeting atherosclerotic plaques [6] or tumor tissues [7]. Due to
their low concentration in blood, a concentrated lipoprotein solution is administered to the animal
model after CA loading. Ferritin, a ubiquitously expressed protein that is the main iron cellular storage
molecule in the body [8], has also been extensively studied for the delivery of biologically active
molecules or metal ions in many biomedical applications. However, in addition to iron, ferritin has
the unique ability to encapsulate and deliver other molecules. Many recent reviews have focused
on various aspects of the use of this nanocage as a drug delivery system [9,10]. This review aims
to discuss the peculiar role of an apoferritin cage not only for the specific delivery of MRI CAs but
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also to obtain significant relaxivity enhancement with consequent efficacy improvement. Ferritin
is a nanocage composed of 24 subunits of heavy (H)- and/or light (L)-chain peptides, with either
ferroxidase activity or iron nucleation ability, respectively. These peptide chains are present in different
ratios in various organs to form a cage architecture of 12 nm in external diameter with an interior cavity
of 8 nm [11]. Although functions of ferritin are traditionally associated with intracellular iron storage,
recent studies have demonstrated ferritin ability for iron delivery and transport [9]. In particular,
studies have demonstrated H-ferritin-mediated iron delivery to the brain through the blood–brain
barrier, demonstrating that H-ferritin can replace transferrin as an iron source for oligodendrocytes
in vitro [12]. Other studies have demonstrated both H- and L-ferritin binding and endocytosis in
a number of different cell types, including hepatocytes [13], reticulocytes [14], lymphoid cells [15],
erythroid precursors [16], and cancer. The receptors involved belong to human scavenger receptor
class A member 5 (SCARA5) [17] for L-ferritin and to murine TIM-2 [18] and human transferrin
receptor 1 (TfR-1) [19] for H-ferritin, respectively. Thus, without any modification of the protein
cage, it can be exploited for the delivery of CAs in pathologies overexpressing these receptors [20]
(Figure 1). Furthermore, perturbations in cellular ferritin are emerging as an important element in
the pathogenesis of neurodegenerative and vascular diseases, inflammatory states, and breast, colon
and liver cancers [21]. These perturbations can be related to an up or downregulation of ferritin cell
receptors. In fact, it is well known that fast proliferating tumor cells abnormally express TfR-1 due to
their increased iron consumption [22]. Moreover, there is a highly variable expression of SCARA5 by
different mammary or hepatoma cancer cells that plays a critical role in pathology progression and
metastasis by inactivating different signaling pathways [23,24]. However, the expression of TfR-1 and
SCARA5 on both normal hepatocytes and other tissues can increase ferritin clearance through the
bloodstream, thus reducing its accumulation at the target site. To increase targeted ferritin delivery,
more selective ligands of cell surface markers, such as peptides and antibodies, have been conjugated
to the external surface of ferritin [25]. In this contest, Khoshnejad M. et al. have shown high pulmonary
endothelial targeting in vivo, with no noticeable undesired effects, by functionalizing ferritin with
antibodies specific for ICAM-1 [26]. The present review aims to highlight recent advances achieved
using both H- and L-ferritins, loaded with paramagnetic metals or complexes, as highly sensitive MRI
probes (Figure 1). Loading into the protein cavity enables the imaging probes to report on ferritin
receptor expression that is involved in the progression of many diseases.
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Figure 1. Schematic representation of the use of ferritin for diagnostic and theranostic purposes.
The protein cage can be loaded with magnetic resonance imaging (MRI) contrast agents containing
paramagnetic ions (Gd, Fe, Mn), magnetic nanoparticles (MNPs) and drugs. Human transferrin
receptor 1 (TfR-1) and human scavenger receptor class A member 5 (SCARA5) are the natural ferritin
cell-surface receptors for H- and L-ferritin subunits, respectively.
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2. Gd-Loaded Apoferritin
One of the basic issues of fundamental importance in the development of Gd(III)-based MRI
contrast agents is the search for very high relaxivities [27]. The intrinsic proton relaxivity of Gd ions is
decreased by the formation of chelates such as Gd-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic
acid (Gd-DOTA) and Gd-diethylenetriaminepentacetatic acid (Gd-DTPA) (Figure 2A,B), leading to
their administration in large doses in the clinic and, therefore, enhancing the risk of toxic effects.
A possible strategy to enhance the efficiency and increase the specific accumulation of CAs is based
on their inclusion into the apoferritin cavity. This central core (of ca. 8 nm) can hold many CA units.
At the intersection of the subunits, channels of 3–4 Å in diameter allow the diffusion of water into the
cavity but not of larger molecules i.e., with the size of commonly used CAs (8–9 Å) [28].
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Using this method, Aime and coworkers obtained the entrapment of ca. 10 Gd-2,2′,2″-[10-(2-
hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid (Gd-HPDO3A) units per 
apoferritin molecule (Gd-Apo). Gd-HPDO3A (Figure 2C) is a commercially available (trade name 
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(C) Gd-HPDO3A, (D) Gd-DOTA-tetra(amide), (E) Gd- e2 2A and (F) Gd-BOPTA.
Different strategies for trapping s all molecules in the apoferritin core were reported [29].
The procedure first indicated by Aime and coworkers [30] consisted of the dissociation of horse
spleen apoferritin (HoS-apoferritin) into subunits at pH 2 followed by its reassociation at pH 7.4.
In this way, the CA molecules that dissolved in the solution were trapped within its interior (Figure 3).
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Figure 3. Schematic representation of the dissociation of apoferritin into subunits at pH 2, followed by
its reforming at pH 7. In this way, the solution components were trapped within its interior. Reproduced
with permission from [30]. Copyright John Wiley and Sons, 2002.
Using this ethod, Aime and coworkers obtained the entrapment of ca. 10 Gd-2,2′,2”-[10-(2-
hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid (Gd-HPDO3A) units per
apoferritin molecule (Gd-Apo). Gd-HPDO3A (Figure 2C) is a commercially available (trade name
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ProHance®) neutral complex that displays one coordinated water molecule in fast exchange with bulk
water. When encapsulated in the interior core of apoferritin, Gd-HPDO3A has a longitudinal relaxivity
(r1) of 80 ± 5 mM−1 s−1 per Gd3+ atom at 0.5 T and 25 ◦C, a value that is almost 20 times higher with
respect to the free complex in water (4.2 mM−1 s−1). The success of this cavity to attain high relaxivities
results from the exploitation of a large protein surface strongly interacting with the paramagnetic
complexes. Such unusual high relaxivity cannot be explained by standard paramagnetic relaxation
theory for Gd(III) chelates containing a single inner-sphere water molecule. To explain this relaxivity,
Aime and coworkers highlighted the importance of additional contributions assigned to water
molecules and exchangeable protons on the protein surface in the proximity of the Gd(III) complex
binding site(s). The loading of 8–10 Gd-HPDO3A units inside the protein cavity generates various
interactions between the paramagnetic centers, the water molecules (free moving within the cavity or
H-bonded to the inner protein surface), and exchangeable protons, in turn producing an overall highly
relaxing sink. The fundamental role of these second sphere protons in the determination of such a
large relaxivity increase was confirmed by Vasalatiy et al. [31] a few years later. In fact, they repeated
the same entrapment experiment using a Gd-DOTA-tetra(amide) (1,4,7,10-tetraazacyclododecane
tetrakis (ethyl-acetamidoacetate)) (Figure 2D) without inner sphere-coordinated water molecules
(q = 0) obtaining an r1 of the encapsulated complex of 60 ± 4 mM−1 s−1 (whereas the free complex
r1 was 2.1 mM−1 s−1, 0.5 T, 25 ◦C). The authors concluded that the substantial increase in relaxivity
must be attributed to: (i) a rapid prototropic exchange between the internal protein surface and
freely moving water confined in the inner-core and (ii) further enhancements related to the rotational
slowing of the complex due to the interaction with the inner-core surface residues. In 2010, Fries
and Belorizky [32] presented a theoretical model applied to the apoferritin system to calculate the
relaxivity of Gd(III) complexes encapsulated inside water-permeable nanovesicles. In agreement with
Aime et al. [30], the 1/T1 nuclear magnetic resonance dispersion (NMRD) theoretically predicted
profile of Gd-HPDO3A trapped inside apoferritin vesicles matched perfectly with the one acquired
experimentally. The model showed that the second/outer-sphere relaxivity dominates with respect to
the inner-sphere contribution. To improve the entrapment efficiency, Makino and coworkers [33] took
advantage of the intrinsic property of apoferritin to condense cations in its cavity. A positively charged
Gd-4,10-dimethyl-1,4,7,10-Tetraazacyclododecane-1,7-diacetic acid (Gd-Me2DO2A) (Figure 2E) was
used for this purpose. Using the pH-dependent encapsulation procedure, about 11 Gd-Me2DO2A
units were trapped inside the protein cavity but the apoferritin recovery rate was low (25%). Thus, the
authors modified the reassembling protocol by slowly increasing the pH from 2 to 4 before the addition
of the positive Gd-chelate. At pH 7, the apoferritin recovery rates increased over 90%. The highest
Gd-Me2DO2A r1 (35.9 mM−1 s−1 at 1.5 T) was obtained when a maximum of 11 units were loaded in
the protein cavity. Increasing this number from 11 to ca. 36 caused an r1 decrease to 19.6 mM−1 s−1.
The authors surmised this decrease with a limited number of strong Gd-Me2DO2A binding sites on the
apoferritin inner surface. After the encapsulation of Gd-Me2DO2A, the apoferritin outer surface was
modified with dextran to enhance the in vivo blood clearance time. The protein diameter increased up
to 30 nm. A completely different approach was reported by Sanchez et al. [34] In this study, Gd(III)
metal oxide or oxyhydroxides were formed directly inside the apoferritin cavity after the addition of
Gd(NO3)3 at pH 8 to the protein solution. The Gd(III) not trapped inside the cavity but weakly bound
to the external protein surface was eliminated by adding ethylenediaminetetraacetic acid (EDTA) to
the Gd(III)-apoferritin solution. Finally, a total of 1700 Gd(III) per protein was obtained.
Besides the establishment of a well-designed model with high relaxivities, Gd-loaded apoferritin
was used to obtain an in vitro and in vivo contrast enhancement in MR images of tumors.
Makino et al. [33] performed MRI studies of adenocarcinoma-bearing mice and showed that the
GdMe2DO2A apoferritin system successfully accumulated in the tumor region as a consequence of the
enhanced permeation and retention effect. A well detectable signal intensity (SI) enhancement of the
tumor region was measured using a Gd dose of 0.02 mmol/kg, i.e., five times lower than that used
with standards CAs. Geninatti Crich and coworkers [35] developed a targeting method to visualize
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angiogenesis by MRI through the specific recognition of the neural cell adhesion molecule (N-CAM),
which is stably expressed by neoformed tumor endothelial cells (TECs). In this study, streptavidin was
used as a linker between a biotinylated-apoferritin, loaded with Gd-HPDO3A, as described above [28],
and a biotinylated targeting peptide (C3d-Bio) able to bind N-CAM molecules on TECs. Gd-HPDO3A
remained entrapped in the protein cavity also after its binding to the N-CAM receptor, as demonstrated
by its NMRD profile that showed the same bell-shaped behavior with an r1 hump at 0.8 T (35 MHz)
observed in buffer solution (Figure 4).
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In vivo, a marked SI enhancement (>30%) was observed in the tumor region 5 h after the C3d-targeted
Gd-loaded apoferritin administration with respect to the non-targeted one (3–5%), in a mouse model of
tumor angiogenesis obtained by injecting TEC cells subcutaneously, in matrigel, in Severe Combined
ImmunoDeficient (SCID) mice (Figure 5). The Gd dose administered (0.01 mmol/kg) was 10 times lower
than the dose currently used for Gd-based CAs in clinical protocols (0.1 mmol/kg).
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Figure 5. (A) MRI signal intensity (SI) enhancement of tumors in SCID mice grafted with TECs treated
with Gd-loaded apoferritin targeted and nontargeted to N-CAMs. MR T1-weighted images of tumors
done before (B) and 5 h after (C and D) administration of C3d-Bio/streptavidin/Gd-loaded apoferritin
(20:1:1), which corresponds to a Gd dose of 0.01 mmol/kg 10 times lower than that used in clinical
protocols. The tumors are outlined in blue; red highlights the areas where the signal is 3 signal
difference (SD) more intense than the precontrast tumor intensity (D). Reproduced with permission
from [35]. Copyright American Association for Cancer Research, 2006.
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3. Mn-Loaded Apoferritin
Concerns over the relationship between Gd and nephrogenic systemic fibrosis and the increased
risk of toxicity caused by Gd deposition in the brain are increasing efforts to develop alternative CAs
that do not contain Gd [36]. Manganese(II) is a paramagnetic metal and may be considered a good
candidate because it is an essential metal in biological systems, with efficient cellular storage/excretion
routes for controlling its homeostasis. Unfortunately, when manganese is administrated intraveneously
as MnCl2, it shows a low Lethal Dose 50 (LD50) of 0.32 mmol/kg in mice [37]. An Mn-loaded
HoS-apoferritin system (Mn-Apo) was proposed by Kalman et al. [38] to combine low toxicity with high
efficacy. Following a previously reported procedure [39], MnOOH-loaded apoferritin was prepared
by incubating the protein at pH 9 in MnCl2 solution under air. After a week, a reduction/dissolution
process was carried out by adding an excess of 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic
acid (TETA) ligand to eliminate Mn(II) ions from the protein shell outer surface and, at the same time,
to partially dissolve nanosized β-MnOOH crystals trapped within the protein cavity via the reduction
of Mn(III) to Mn(II) (Figure 6).
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The selective uptake of Mn-Apo through SCARA5 receptors was also investigated in human
breast cancer cells, MCF7 and MDA-MB-231 [41]. The high expression of SCARA5 in MCF7 cells
generated hyperintense signals in MR images (7T) with respect to MDA-MB-231 cells that display
a lower expression. The longitudinal relaxation rate 1/T1 = R1 (s−1) increased proportionally for
MCF7 cells, increasing the concentration of Mn-Apo added to the medium and remained low and
constant for MDA-MB-231 cells. Moreover, Szabo et al. [42] demonstrated that Mn–OOH-loaded
apoferritin can be used as a sensor of melanin formation in melanocytes. The oxidative process
during melanin formation displayed suitable redox characteristics for which the involved reduced
species may act as reductant agents for Mn(III) ions. The ability to reduce the MnOOH core was
determined previously in an in vitro assay showing an increased Mn-Apo solution R1 (from 0.5 to
6 s−1) after the addition of L-3,4-dihydroxyphenylalanine (L-DOPA) and tyrosinase. Thereafter, the
potential of Mn-Apo was assessed on melanogenic and non-melanogenic cells in in vitro and in vivo
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studies. Mn-Apo was able to discriminate between the two cell clones in MRI experiments, upon
the incubation of 0.4 mM MnOOH–Apo for 4 h at 37 ◦C. Similarly, when injected intratumorally in
melanoma tumor-bearing mice, the T1-weighted MR images (1T) showed a marked SI enhancement in
the tumor region but not in mice muscle, injected with the same dose, thus indicating the specificity
of Mn-Apo as a MRI sensor of the melanine formation process [42]. Finally, another example of the
use of apoferritin loaded with a MnOOH core was reported by Patrick et al. [43]. The TIM-2 receptor
(T-cell immunoglobulin and mucin domain containing protein 2) that mediates H-ferritin endocytosis
was exploited by the authors as an MRI-based gene reporter [43]. HEK 293T (human embryonic
kidney) cells modified to express the TIM-2 transgene were incubated for 30 min in the presence of
MnOOH–Apo. The HEK-293T-expressing TIM-2 cells showed an increased signal in the T1-weighted
images and a decreased signal in T2-weighted images acquired at 7T, three-fold higher and two-fold
lower in R1 and R2 compared to control cells, respectively. However, the effect of MnOOH–Apo on
cellular growth and viability limited its in vivo application. An alternative approach proposed by
Sana et al. [44] was based on the use of an engineered A. fulgidus ferritin (AfFtn-AA), a tetracosameric
ferritin known to form a tetrahedral cage presenting four openings (45 Å diameter). This protein
exists as a dimer in low ionic strength buffer but in the presence of divalent metal ions, such as
MnCl2, subunits self-assemble in a 24-meric protein cage. A total of 500 Mn atoms were encapsulated
per protein cage and the mineral core formation was detected by transmission electron microscopy
(TEM). The longitudinal r1 and transverse r2 relaxivities were 10 and 74 mM−1 s−1 (3T), respectively,
equivalent to 6650 mM−1 s−1 and 47,200 mM−1 s−1 per apoferritin molecule.
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4. Magnetoferritin
Ferritin contains a superparamagnetic ferrihydrite crystal (5Fe2O3·9H2O) which increases the R2
of solvent water protons, causing a negative contrast in the corresponding images. In fact, the presence
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of ferritin within tissues influences the SI in T2-weighted MRI of the liver, spleen, and brain—the
organs where ferritin concentration is highest [45,46]. The effect of ferritin on MRI T2-contrast increases
with the magnetic field strength. Water-soluble magnetic iron oxides, with a significantly higher
sensitivity, which are coated with biocompatible polymers, have been used as highly sensitive MRI
CAs in many preclinical and some clinical studies [47]. Depending on their size, they are called
small or ultrasmall particle iron oxide (SPIO or USPIO) particles. They are taken up efficiently by
the monocytes–macrophages system, so they are good candidates for the imaging of inflammation.
Although two of the commercially available agents (endorem, and resovist) were withdrawn from
the market mainly due to economic reasons and some side effects [48], SPIO and USPIO particles
continue to be under preclinical investigation with the aim to improve their efficacy and safety.
As ferritin is the final iron form after the degradation of these iron oxide particles [49], Valero et al.
proposed to encapsulate the particles (of 4 and 6 nm) directly in the protein cavity to prevent their
degradation [50]. The pH-driven horse spleen apoferritin disassembly/assembly protocol described
above was used and the obtained loaded protein was called apomaghemite (APOMAG). Thereafter,
the efficiency in generating T2* contrast in MRI images was evaluated after their injection into mice.
The contrast produced on T2* images was very similar to that obtained after the injection of endorem
(the SPIO commercially available reference particle). These results suggested that APOMAG samples
are promising CAs. Moreover, APOMAG was functionalized with carbohydrate moieties (mannose and
N-acetyl glucosamine) on its external surface through binding to amine groups located at the external
protein shell. The retention of the recognition abilities of the carbohydrate-functionalized APOMAG
was demonstrated by measuring its strong affinity with the corresponding carbohydrate-binding
lectins [50]. Moreover, Masaki et al. [51] proposed the use of a recombinant human H-chain ferritin
(rHFn)-iron oxide nanocomposite as an MRI contrast agent for labeling macrophages. Magnetites or
maghemites with narrow size distribution and low T2* were synthesized in the interior cavity of rHFn.
The mineralized protein cages were readily taken up by macrophages in vitro and provided significant
T2* signal loss of the labeled cells, encouraging further investigation to assess the inflammatory disease
status such as macrophage-rich atherosclerotic plaques in vivo [51]. Recently, ultrafine H-ferritin-based
iron oxide nanoparticles with hematite and/or maghemite cores (diameters < 5 nm) were proposed by
Yao et al. [52] as positive CAs for magnetic resonance angiography (MRA). The ferritin nanoparticles
with a higher r1 value and lower r2/r1 ratio were selected for MRA experiments. High spatial resolution
steady-state images of the vascular compartment were obtained from 3 min up to 2 h after a single
injection of these nanoprobes, mainly due to the long-term blood pool imaging. The single injection
and long-term imaging feature suggest their obvious advantages in MRA application compared with
other small-sized Gd-based CAs [52].
5. Ferritin as an Endogenous MRI Reporter for Gene Expression Imaging
Reporter genes allow the noninvasive study of the dynamics of gene expression and can be
exploited as helpful tools to validate the efficacy of gene therapy and to monitor cell fate during
treatment. Classical reporter genes code for fluorescent proteins, such as Green Fluorescent Protein
(GFP) and enzymes that convert substrates into luminescent or colored products such as firefly
luciferase. Therefore, optical imaging represents the main tool to monitor gene expression in vivo. One
of the major drawbacks of this technique is the limited resolution and sensitivity caused by the depth
of penetration and scattering of light. Instead, MRI could represent the ideal technique to monitor gene
expression, due to its high spatial resolution, tissue penetration and contrast. Ferritin was suggested
as a candidate endogenous reporter gene for the in vivo imaging of gene expression [53]. In particular,
the induced expression of ferritin leads to a transient decrease in the iron content of the cell, which
is physiologically balanced by the subsequent increase in the expression of iron importers, such as
TfR-1 [53]. This leads to a net accumulation of iron inside the cell, which can be safely allocated inside
ferritin. The accumulation and redistribution of iron alter MR relaxation rates, causing a negative
contrast. The use of ferritin as gene expression reporter has been mainly exploited to study tumor
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biology and to follow the fate of stem cell grafts. Cohen and coworkers [54] designed a multimodal
reporter gene where ferritin H-chain and the enhanced green fluorescent protein (EGFP) expression
was controlled by tetracycline (TET) in C6 rat glioma cells. When ferritin was overexpressed in the
absence of TET, r2 significantly increased which allowed the tumor growth course to be followed [54].
In tumor biology, the ferritin reporter gene has also been used to visualize the recruitment of fibroblasts
from local or remote tissue to the angiogenic rim of tumors [55]. Vandsburger et al. [55] demonstrated
that ferritin heavy chain overexpression in monkey kidney cell line (CV1) fibroblasts enhanced iron
uptake and retention, causing a detectable contrast in T2*-weighted MR images. r2 mapping also
revealed the spatiotemporal kinetics of fibroblast recruitment even at low cellular densities, allowing
the characterization of the dynamics of the tumor microenvironment.
The imaging of stem cells is important to monitor their delivery, fate and function after
transplantation in the host environment. One critical issue is to be able to distinguish between
live and dead cells after the graft. Direct labeling of stem cells, which consists of the loading of cells
with contrast agents prior to the engraftment, shows some limitations: asymmetric dilution of the
probe with cellular proliferation, persistence of label after cell death, indirect relationship between
signal intensity changes and total number of labeled cells [56]. The use of an endogenous reporter
gene, which is integrated into the genome and continuously expressed, is particularly convenient
to avoid these problems. Iordanova et al. used primary neuronal progenitors expressing a chimeric
ferritin molecule (L*H) to visualize in the mouse brain their migration from the sub ventricular
zone (SVZ) to the olfactory bulb. The L*H showed higher iron loading and significantly higher MRI
contrast enhancement compared to wild-type ferritin, allowing the detection of cell clusters of the
order of 104 cells [57]. They [58] induced ferritin heavy chain (FTH1) expression by using a Tet-On
switch in the C3H10T1/2 cell line. The expression was dose- and time-dependent upon Doxorubicin
administration [58]. Recently, Dai et al. showed that ferritin overexpression through the exogenous
rAdV-mediated FTH1 gene in bone marrow mesenchymal stem cells (BMSCs) resulted in a decrease in
T2 signals acquired at 7T [59]. Zhang et al. [60] transfected neuronal stem cells (NSCs) with a lentiviral
vector carrying both MRI and the fluorescence-imaging reporter gene. MRI and fluorescence imaging
were used to monitor the fate of NSCs after transplantation in rat striatum after acute ischemic stroke
over a long period of time [60]. The use of an endogenous reporter gene is also particularly convenient
to overcome problems related to crossing delivery barriers (i.e., the blood–brain barrier) or short
residence times of contrast agents. This can be particularly useful in neuroscience to study cognitive
processes and complex behaviors. Wu and coworkers [61] generated transgenic mice expressing
ferritin heavy chain and the mKate2 fusion protein reporter gene under the Arc promoter, which
is induced in mammalian brain by increased neuronal activity. After treatment with pilocarpine,
a non-selective muscarinic agonist, an increase in T2-weighted image signal was observed in neurons
of the hippocampal and cortex regions [61].
6. Theranostic Use of Ferritin
Personalized medicine is one of major expectations of nanomedicine, enabling diagnostics and
therapeutics to target individual needs and developing a truly “patient-friendly” medical approach [62].
At the same time, the rapidly evolving field of molecular imaging promises improvements in patient
screening and early diagnosis [63,64]. The combination of diagnostic and therapeutic agents within a
single formulation (i.e., dendrimers, micelles, liposomes, metallic and inorganic nanoparticles, carbon
nanotubes), provides real-time feedback on the pharmacokinetics, the target site localization and the
(off-target) healthy organ drug accumulation [65,66]. In this context, protein-based nanocages are a
good candidate as potential devices for theranostics purposes. In particular, ferritin, due to properties
such as its high stability and biocompatibility, has emerged also as an excellent and promising drug
carrier [67]. Although Doxorubicin encapsulation in ferritin nanocages represents the most extensively
investigated system [29,68,69], there are also some interesting results reporting the efficacy of the
encapsulated Cisplatin [70–72]. Several studies have provided strong evidence of an enhanced efficacy
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of chemotherapeutic therapy after their encapsulation in ferritin-based nanoparticles, not only for
anticancer drugs, but also for other active molecules [29]. The first example of the use of apoferritin
to deliver therapeutic and imaging agents simultaneously was proposed to target hepatocytes
by SCARA5 via the ferritin-transporting route [73]. Gd-HPDO3A (Figure 2C) and Curcumin,
a polyphenolic substance endowed with multiple pharmacological actions (namely, antioxidant,
anti-inflammatory, antineoplastic), have been loaded using the pH-based disassembling/reassembling
protocol. The theranostic efficiency of Curcumin and Gd-HPDO3A-loaded apoferritin (Apo-CUR-Gd)
has been validated on thioacetamide-induced hepatitis. Mice pre-treated with intraperitoneal
administration of Apo-CUR-Gd showed significantly attenuated hepatic injury as assessed by
measuring alanine aminotransferase (ALT) activity in plasma and by histological assessment. The
encapsulation of Curcumin inside the apoferritin cavity significantly increases its stability and
bioavailability while maintaining its therapeutic anti-inflammatory properties [73]. More recently, the
theranostic potential of Apo-CUR-Gd was assessed on cancer stem cells (CSCs) [74]. Most evidence
suggests that CSCs have the unique biological properties necessary for tumor maintenance and
spreading, and function as a reservoir for the relapse and metastatic evolution of the disease by virtue of
their resistance to radio- and chemo-therapies [75]. The CSC-enriched tumorspheres from breast cancer
cell lines display an increased L-ferritin uptake capability compared to their monolayer counterparts
as a consequence of the upregulation of the L-ferritin receptor SCARA5 [74]. This theranostic
system was able to impair the viability and self-renewal of tumorspheres in vitro and to induce
the regression of established tumors in mice. Apo-CUR-Gd not only has strong therapeutic potential
due to specific targeting but also the advantage of improved Curcumin bioavailability. Moreover,
a completely different approach was used by Ruggiero et al. [76] for theranostic purposes. Polylactic
and glycolic acid nanoparticles (PLGA-NPs), coated with L-ferritin, were exploited for the simultaneous
delivery of paclitaxel (PTX) and an amphiphilic Gd(III)-based MRI contrast agent into human
breast cancer cells (MCF7). Exploiting N-hydroxysuccinimide (NHS) activated carboxylic groups,
L-ferritin was covalently conjugated to the external surface of PLGA-NPs. The results confirmed that
ferritin-nanoparticles have many therapeutic advantages with respect to both albumin-decorated and
non-decorated particles and the injectable formulation of the drug (Paclitaxel Kabi), especially at short
incubation time. Ferritin moieties endow PLGA-NPs with targeting capability, exploiting SCARA5
receptors overexpressed by most cancer cells, which results in an increased paclitaxel cytotoxicity
in comparison to the clinically used formulation. Moreover, protein coating increased nanoparticle
stability, thus reducing the fast and unspecific drug release of this kind of nanosystem before delivery
to the target site. The specificity of this theranostic nanoparticle has been demonstrated by evaluating
the signal intensity enhancement on the T1-weighted MRI images of labeled MCF7 cells, compared to
MDA-MB 231 breast cancer cells used as negative control due to their lower SCARA5 expression [76].
Finally, Cutrin et al. [77] proposed iron-loaded H- and HoS- (Horse Spleen, containing 85% of L
subunits) ferritins as natural nano-theranostic agents exploiting their ability to deliver iron into
epitheloid cervix carcinoma (HeLa) cells expressing both TfR-1 and SCARA5 receptors, allowing
H- and L-cage internalization, respectively. It was reported that iron starvation can damage cell
development and growth, whereas excessive iron accumulation leads to cytotoxicity, through the
over-production of free radicals. Moreover, tumor cells appear unable to properly manage iron
excess removal, basically, as a consequence of ferritin downregulation observed in many human
cancers [78]. Both H- and HoS-ferritins showed high cytotoxicity in HeLa cells but very different cell
death profiles [77]. The higher H-ferritin toxicity in cells resulted in a submicromolar concentration for
the presence of a pool of non-biomineralized iron ions bound at the ferroxidase catalytic sites, absent
in HoS-ferritins, that was readily released during the endosomal-mediated internalization. Moreover,
due to the ability of the iron core in ferritin to act as a negative MRI contrast agent, ferritins can be
proposed as natural theranostic agents that do not need any further modifications. The amount of
H- and HoS-ferritins taken-up by HeLa was enough to be detected by T2-weighted MRI experiments
after 24 h incubation in the presence of 0.38 mM iron-loaded ferritins (Figure 8). As expected, cells
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labeled with HoS-ferritin loaded with a more pronounced iron oxide core (1000 Fe atoms) are more
hypointense than those labeled with H-ferritin (350 Fe atoms).
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